Neko Health is the preventive-health clinic co-founded by Spotify’s Daniel Ek – a one-hour, ~£299 full-body scan plus a same-visit doctor consult. The experience reviews well; the claim that it keeps healthy people alive longer does not yet have the evidence behind it. We booked the Stockholm scan in June 2026; here is what it is actually like.
Agewell booked and completed the Stockholm scan in June 2026. This profile combines that visit with current published prices, program details, public records and independent reporting. Each factual claim links to its source and review date.
“A genuinely slick, fairly-priced annual health MOT with real appeal – and a real caveat. The skin archive, the peer benchmarks and the doctor time are worth it; the missing advanced markers and the longevity claim are where the polish outruns the substance.”
The short answer
Clinic locations
Announced, not open
An official clinic source presented the location as announced, coming soon or waitlist-only. Agewell does not count it as operating.
Official location source: Neko Health (official)
Apply Agewell’s 8-point evidence checklist to this clinic →
Programs, visits and memberships the clinic lists publicly, with prices, inclusions, caveats and sources.
Published figures are starting prices. Ask the clinic for a dated, itemized total covering mandatory extras, follow-up and cancellation terms.
Starting price only
How we checked this profile
Agewell records public prices, what each clinic provides, clinician involvement, follow-up and unanswered questions separately. Every factual statement links to the source that supports it. Information supplied by a clinic is labelled and does not change our editorial verdict without independent support.
£299 (London) · 2,750 SEK (Stockholm) · New York City price not published
A complete first-year price including add-ons, retesting and outside referrals is not publicly available.
Single prepaid visit. About 1 hour.
Sensor scan, instant blood markers and same-visit doctor review
Same-visit doctor review and a named written summary. Direct clinician time was not published in a comparable format.
The scan includes a clinician review, an action plan and free follow-ups or referral support when indicated; the scope and cost of longer-term outside care are not disclosed.
Neko reports improvements among 1,469 returning Stockholm members, including 5 of 7 tracked biomarkers. Neko describes the analysis as not a scientific study and says it had no control group; no comparison protocol or complication report was provided.
Who arranges and pays for care after an outside referral, when should tests be repeated, and which patient outcomes does Neko publish?
We booked the Stockholm clinic and went in June 2026. The space is pure Scandinavian white, closer to a modern massage studio than a hospital: shoes off, a short wait, then a guide (nurse or technician, it was not made clear) walks you through the hour. You change into a robe.
The scan is the set piece. You stand in your underwear on floor markings inside a large ring, a little like an airport body scanner, and the walls rotate around you while it captures something over two thousand photographs of your skin to map every mole and lesion. It gets mildly warm and you keep your eyes closed against the light, but nothing about it is unpleasant, and it is over in a few minutes.
Then you lie on a bench beside it. Blood pressure is taken with four cuffs at once, one on each arm and each leg, alongside several ECG leads, and a laser reads your pulse. They draw blood and, as a genuinely good touch, fire the sample up a pneumatic tube to the lab on the spot. A recorded female voice narrates in English with a knowing, retro-futuristic tone. The doctor comes in last, reviews the flagged moles under a dermatoscope, and listens to and records your heart.
Afterward you dress (the changing room has wireless phone charging, a nice detail) and sit in a small room walking through your results like an interactive slideshow: blood lipids, inflammation, the skin-laser readings, grip strength and a handful of other values. Each metric is benchmarked against members your age, which is quietly addictive: land in the top 15% on grip strength and you immediately want the top 10. A few days later you also get a written summary from a named doctor and the Neko medical team, with plain-English interpretation and lifestyle recommendations tailored to your history. The presentation, and the fact that a real physician signs the read, are the most polished parts of the hour.
It is pleasant, fast and beautifully presented, and at 2,750 SEK (about £299) it is fairly priced for what it is. The panel is broader than we first assumed: a full lipid breakdown, HbA1c and glucose, a complete white-cell differential with hs-CRP and hemoglobin, oxygen saturation, an ankle-brachial index, a full ECG readout with a heart-sound recording, eye pressure, grip strength and a mapped count of every skin lesion. What it skips is depth, not breadth. There is no ApoB and no Lp(a), the advanced lipid markers a prevention-first clinic should lead with in 2026.
Our honest read in 2026: for raw depth you can still out-test it by ordering an advanced panel yourself, ApoB, Lp(a) and a fuller metabolic workup, and running the results through a good model. What Neko bundles that you cannot easily replicate is the imaging, the full-body skin map and calm doctor time in one polished hour. Where it earns its place is that skin archive: the scan catalogued more than 650 individual skin changes, none of which looked dangerous, and having that baseline saved to compare year over year is the real value. Go for the skin tracking, the convenient baseline and the doctor time, not for a leap in diagnostics. And the human read is better than the gadgetry suggests: the written summary flagged a measurement artifact in the automated blood pressure and explained a high BMI through body composition rather than the raw number, the kind of context a wall of numbers alone does not give you. For now it is more polish than breakthrough, presented exceptionally well, and a category worth watching as the technology matures.
A single, prepaid, non-invasive scan plus a same-visit doctor consult, about an hour in total with results on the day. It is one visit, not a membership, though most customers rebook annually. Here is the full panel as it appeared on our own dashboard in June 2026, grouped the way Neko presents it.
Heart and circulation: blood pressure, a derived heart age, oxygen saturation, ankle pressure and the ankle-brachial index, an early marker of peripheral arterial disease.
Heart rhythm: a full resting ECG with the trace, plus the underlying intervals broken out – pulse, conduction time, ventricular activation and recovery time – and a short heart-sound recording the doctor listens back to.
Blood lipids: a complete panel of total cholesterol, HDL, LDL, non-HDL and triglycerides. Notably not ApoB or Lp(a), the advanced markers a prevention-first clinic should lead with in 2026.
Metabolic: HbA1c and fasting glucose. Immune system and blood count: white cells with the full differential (neutrophils, lymphocytes, eosinophils and basophils), hs-CRP for inflammation, and hemoglobin.
Body and function: weight, BMI, grip strength on each hand, and eye pressure. Skin: a full-body photographic map of every mole and lesion, flagged for the doctor and archived for year-over-year comparison.
What you get back is two things. An interactive dashboard where each value carries a plain status – optimal, normal, or one to monitor – and a benchmark against members your own age and sex. And, a few days later, a written summary from a named doctor and the Neko medical team: a plain-English read of your strong and weak points, what to watch, and lifestyle recommendations set against your own history.
Published price: £299 in the UK and 2,750 SEK in Sweden – notably transparent for the category, and cheaper than buying mole-mapping, blood tests and an ECG separately. Neko operates in Stockholm, London, Manchester and Birmingham. Its official U.S. page says New York City is coming in 2026 and offers a waitlist; no U.S. price is published, so the UK and Swedish prices must not be treated as New York pricing.
The scanner uses 70+ sensors capturing on the order of 50 million data points per visit, analysed by software and reviewed with a doctor. Co-founded in 2018 by Daniel Ek and CEO Hjalmar Nilsonne, Neko followed its $260M Series B in January 2025 with a $700M Series C in July 2026. Those financing and expansion figures describe company scale, not medical effectiveness.
First-hand accounts (Sifted, Marie Claire, Get the Gloss) are warm: a calm, fast, almost spa-like experience, generous and non-judgemental doctor time, and good value versus à-la-carte equivalents. Most journalists came away "largely healthy" with minor flags. At least one customer’s early-stage melanoma was reportedly caught by the scan – a real-sounding anecdote, not a published outcome.
The harder-nosed coverage is more reserved. The FT noted the scan is "not designed to detect many medical conditions" and that in well-resourced public systems most of these tests would be offered on indication anyway.
This is where we give the criticism equal billing. There is no published evidence that scanning asymptomatic, mostly-healthy people extends life, and screening-medicine experts are pointed: reviews of whole-body screening find no survival benefit and tumour-detection rates under ~2%, while false positives and incidental findings drive follow-up tests and biopsies that usually find nothing. One UK screening expert called Neko, on current evidence, "more likely a waste of money and time," with "an obvious risk… of overdiagnosis and overtreatment."
One fairness point: Neko is a photo, thermal, sensor and bloods scan – not whole-body MRI or CT, so it carries no radiation and the harshest imaging critiques do not map perfectly. But the core logic (overdiagnosis, false positives, no proven mortality benefit, system spillover onto GPs) still applies. Neko says clinical trials are underway; as of this writing none are published.
A reasonable fit if you want a fast, comprehensive baseline with real doctor time, you have specific risk factors (many atypical moles, family cardiovascular or metabolic history) you can act on, and you will not spiral over an ambiguous result.
Skip it, or go in clear-eyed, if you are healthy, low-risk and expecting it to "catch cancer early" or add years – there is no evidence it does, and the false-positive tax is real. Anyone prone to health anxiety should weigh that before booking.
Calm and fast. We went in June 2026: shoes off, a robe, then a few minutes standing inside a rotating ring that photographs your whole body to map moles, followed by blood pressure on all four limbs, ECG, a blood draw sent up a pneumatic tube, and a short doctor review. You leave with an interactive slideshow of your results in about an hour.
Neko Health works as a single prepaid preventive-health visit: a fast sensor-based body scan, instant blood markers and a same-visit doctor consultation. The appeal is speed, convenience and a clear baseline, not a proven longevity intervention.
Neko Health can be worth it if you want a structured baseline, skin and cardiovascular checks, transparent pricing and doctor time in one visit. It is weaker if you expect proof that the scan extends life, because that outcome evidence is not published.
Neko Health may flag suspicious skin lesions for doctor review, and at least one public account describes an early melanoma being caught. That is not the same as broad cancer screening: the scan is not a whole-body MRI or CT, and screening healthy people still carries false-positive and overdiagnosis risk.
Neko publishes clear single-visit pricing: about £299 in London and 2,750 SEK in Stockholm at the time of this profile. It has not published a New York City price, so those European prices should not be used as a U.S. quote.
By David Persson · Profile updated 2026-07-15 · Information last checked 2026-07-15 · Prices can change; confirm with the clinic · Work with this clinic? Submit an update
The Agewell Briefing
A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.
One email a week. Unsubscribe with one click.